Intra-arterial Hepatic Bevacizumab and Systemic Chemotherapy
The purpose of the study is to assessed the efficiency of treatment based on the objective response rate (RECIST 1.1)
Colorectal Neoplasms
DRUG: Bevacizumab|DRUG: Capecitabine|DRUG: Irinotecan
Efficiency of treatment based on objective response rate, Every 9 weeks from the start to tumoral progression
Treatment toxicity based on NCI-CTC v4.0, Every 3 weeks from the start to tumoral progression or toxicity preventing further processing|Progression Free Survival, Every 9 weeks form the start to tumoral progression|Hepatic metastasis resection rate, Assessed up 6 months after the end of treatment
Total area under the curve of contrast-enhanced liver ultrasound, Assessed up in baseline, D7, D14, W4, W7 and every 9 weeks up to progression
The purpose of the study is to assessed the efficiency of treatment based on the objective response rate (RECIST 1.1)